Particulate adjuvants have shown increasing promise as effective, safe, and durable agents for the stimulation of immunity, or alternatively, the suppression of autoimmunity. Here we examined the potential of the adjuvant carbonyl iron (CI) for the modulation of organspecific autoimmune disease-type 1 diabetes (T1D). T1D was induced by multiple low 
Particulate adjuvants have shown increasing promise as effective, safe, and durable agents for the stimulation of immunity, or alternatively, the suppression of autoimmunity. Here we examined the potential of the adjuvant carbonyl iron (CI) for the modulation of organspecific autoimmune disease-type 1 diabetes (T1D). T1D was induced by multiple low doses of streptozotocin (MLDS) that initiates beta cell death and triggers immune cell infiltration into the pancreatic islets. The results of this study indicate that the single in vivo application of CI to MLDS-treated DA rats, CBA/H mice, or C57BL/6 mice successfully counteracted the development of insulitis and hyperglycemia. The protective action was obtained either when CI was applied 7 days before, simultaneously with the first dose of have been identified to have adjuvant activity (Petrovsky & Aguilar, 2004) .
The use of particulate adjuvants offers an interesting opportunity to enhance, or alternatively suppress the immune responses (Langridge, Dénes, & Fodor, 2010) . Several mechanisms of adjuvant-induced immune response have been proposed: the mode of antigen delivery, activation of innate immunity via pattern recognition receptors such as Toll-like (Madan-Lala, Pradhan, & Roy, 2017) or NOD-like receptors (Girardinet al., 2003) , increasing the antigen uptake by antigen-presenting cells (APC), altering the cytokine expression by secondary stimulation of APC (Perriconeet al., 2013) . As strong activators of immune response, adjuvants' use has been mandatory in the induction protocols of many experimental models of autoimmune diseases, such as experimental autoimmune encephalomyelitis (EAE), neuritis, uveitis, thyroiditis, and orchitis (reviewed in Billau & Matthys, 2001; Stratmann, 2015) . However, opposing effects were also observed as exposure to complete Freund's adjuvant (CFA) was shown to suppress the severity of EAE in rats and T1D development in BB rats and NOD mice (Kies & Alvord, 1958; Lee, Qin, Priatel, & Tan, 2008; Sadelain, Qin, Lauzon, & Singh, 1990; Sadelain, Qin, Sumoski, et al., 1990) . It has been reported that live Mycobacterium avium or bacillus Calmette-Guerin (BCG) can also suppress T1D development in NOD mice (Martins & Aguas, 1999; Yagi et al., 1991) . Furthermore, recent clinical studies have revealed that BCG vaccination exerted antiinflammatory effects in diseases such as multiple sclerosis or T1D (Lagranderie & Guyonvarc'h, 2014; Ristori et al., 2014) . Although all of the NK cells into the CNS and activation of microglia that leads to EAE development (Miljkovic, Momcilovic, Stanojevic, Rasic, & MostaricaStojkovic, 2011; Staykova, Liñares, Fordham, Paridaen, & Willenborg, 2008) . Interestingly, adjuvant activity was not found in other forms of metallic iron, or other metallic iron suspensions such as iron oxide or iron-dextran (Levine & Sowinski, 1970) . However, the potential role of CI as a modulator of organ-specific autoimmunity has not been investigated so far. To define the role of CI in T1D pathogenesis, we have evaluated the impact of this agent in the animal model of T1D, where the disease was induced by multiple low doses of streptozotocin (MLDS) and determined the possible mechanism of CI action.
| MATERIALS AND METHODS

| Materials and reagents
All chemicals, unless otherwise noted, were obtained from SigmaAldrich (St. Louis, MO), and cell culture reagents were from Life Technologies (Grand Island, NY). CI (Sigma-Aldrich, Steinheim, Germany) was prepared as an aqueous suspension. conditions with an underlying 12-hr day/night rhythm and free access to standard rodent chow and water. Animals were randomly assigned to control or CI groups. All groups were comprised of 7-10 animals.
| T1D induction and treatment protocols
Immunoinflammatory T1D was induced in male C57BL/6 and CBA/H mice and DA rats with MLDS (40 mg/kg bw in C57BL/6 and CBA/H, 20 mg/kg bw in DA rats), i.p, for 5 consecutive days as described previously (Stosic-Grujicic et al., 2001) . Animals were treated with a single i.p. injection of CI (25 mg/kg bw, treatment group) or PBS as a vehicle (control group). Day 0 was the day of the first streptozotocin (STZ) injection. CI was administered in early prophylactic (7 days before first STZ injection), prophylactic (at the same day as the first STZ injection), and therapeutic (5 days after the first STZ shot) manner.
Rodents were monitored for the development of hyperglycemia by weekly measurements of blood glucose levels, using a glucometer (Sensimac, IMACO GmbH, Lüdersdorf, Germany). Animals were considered hyperglycaemic if their blood glucose level was higher than10 mmol/l in non-fasted animals. Toxic diabetes was induced in male C57BL/6 mice with a single i.p. injection of high dose of STZ (200 mg/kg bw). Animals were simultaneously treated intraperitoneally with CI (25 mg/kg bw). Glycemia levels were measured 3 days after STZ injection.
| Cell preparation
Ex vivo analysis was performed on MLDS-induced C57BL/6 mice on day 15 of post-diabetes induction and after prophylactic CI treatment.
Animals were killed by cervical dislocation and peritoneal cells (PC)
were collected by lavage of peritoneal cavity with cold PBS containing heparin (5 U/ml). Single cell suspensions from spleen, pancreatic lymph nodes, Peyer's patches, mesenteric lymph nodes, and pancreasinfiltrating mononuclear cells (PIMC) were obtained as previously described (Nikolic et al., 2014; Stanisavljević et al., 2017) . 
| Histological analysis
To assess the incidence of inflammatory changes and the degree of islet cell destruction, histologic sections of pancreata (5 µm 
| Assessment of insulin
An ELISA kit (Mercodia, Uppsala, Sweden) was used according to the manufacturer's instructions to determine insulin concentration in the sera of non-fasted mice. Nitrite accumulation, an indicator of NO release in the supernatant, was detected by Griess reaction as described previously (Stojanovic, Saksida, Nikolic, Nicoletti, & Stosic-Grujicic, 2012 ).
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| Suppressor assay by PC-LNC co-cultivation
PC were isolated on day 15 from MLDS-induced mice treated or not with CI.
Each PC suspension was a pool from three to five animals. Cells ( 
| Immunofluorescence analysis
The phenotype of SC, PLN, PIMC, and PP, as well as the phenotype of pooled lymph nodes and bone marrow-derived dendritic cells in in vitro experiments was assessed by flow cytometry using the anti-mouse antibodies specific for rat anti-mouse IgG2a F4/80 FITC (eBioscience),
Armenian hamster anti-mouse IgM CD40 APC (eBioscience); goat antimouse IgG CD206-PE (R&D), mouse anti-mouse IgG NK1.1 (BD P h a r m i n g e n ,F r a n k l i nL a k e s ,N J ) ,A rmenian hamster anti-mouse IgG 
| Statistical analysis
Data are presented as means ± SD. Statistical analysis was performed using Statistica 6.0 (StatSoft Inc., Tulsa, OK) software. Statistical comparisons were made by one-way ANOVA followed by Student-Newman-Keuls test for multiple comparisons or by Student's t-test (two tailed), as appropriate. p value less than 0.05 was considered to be statistically significant.
3 | RESULTS
| CI reduces clinical parameters of MLDS-induced diabetes
To investigate the effect of adjuvant CI on the development of murine T lymphocyte-dependent diabetes, C57BL/6 mice susceptible to diabetes induction were inoculated with CI given as a single intraperitoneal injection at a start of diabetes induction with MLDS. Strikingly, whereas blood glucose level in control MLDS-induced mice gradually increased, in mice inoculated with CI after the initial rise, glucose level rapidly decreased resulting in the restoration of euglycaemia ( Figure. Results from one representative out of three experiments are presented as mean ± SD (n =7-10 animals per treatment). *p < 0.05 refers to corresponding MLDS animals
Inoculation of CI (irrespective of delivery time) to CBA/H mice provided a measurable level of protection (Figure 1c ) similar to that obtained in C57BL/6 mice. Also, CI treatment did not interfere with the weight gain of the animals (Figure 1d ). Because rats are more sensitive than mice cells to diabetogenic doses of streptozotocin (Stosic-Grujicic et al., 2001) , the effect of CI in DA rats was further investigated. As in the mouse, a significant suppressive effect had been observed and was similar whether CI treatment started before, or simultaneously with MLDS application (Figure 1e ). In addition, body weight gain was not affected by CI treatment (Figure 1f ).
Thus, in both rat and mouse models of MLDS T1D, the protective effect of single dose of CI was substantial and long-lasting with limited variations of blood glucose levels throughout the entire 42-days follow-up period.
To prove that CI interfered with autoimmune process during T1D development and not with glycemia per se, CI was administered to C57BL/ 6 mice that received toxic dose of STZ (200 mg/kg bw). Indeed, mice in both control group (treated with STZ + PBS) and in STZ + CI-treated group developed hyperglycemia 72 hr after STZ injection (21.9 ± 3.4 vs.
21.1 ± 10.2 mmol/L, respectively, p = 0.876), indicating that CI was unable to alter glycemia in animals with completely destroyed pancreatic islets. (Figure 1i ). Overall, these data indicated that CI treatment preserved islets from autoimmune attack, thus enabling appropriate regulation of plasma glucose level. IL-1β-91 ± 23 pg/ml vs. 99 ± 18 pg/ml, TNF-2309 ± 76 pg/ml vs. 2200 ± 110 pg/ml, and IL-6-1904 ± 148 pg/ml vs. 1951 ± 92 pg/ml).
| CI treatment prevents insulitis and preserves insulin production in MLDS-treated C57BL/6 mice
| The effect of CI treatment on the immune response in the spleen
Also, while CI did not affect the relative sizes of both CD4 
| CI treatment induces in vitro NO-mediated suppressor function of peritoneal cells
Since our results indicated that CI lowers the number of proinflammatory macrophages in the spleen, we further investigated MLDS-induced mice were co-cultured with ConA-stimulated lymphocytes derived from control C57BL/6 mice. As shown in Figure 3b , LNC proliferative response to mitogen was lower in the presence of CI-treated PC when compared to vehicle-treated PC.
In contrast, CI-derived PC released higher concentrations of NO than cells isolated from vehicle-treated mice suggesting that lowered T cell proliferation was a consequence of the active suppression by CI-induced macrophage-derived NO. Figure S1C) . Seemingly, p38 (Supplementary Figure S1D) and ERK mitogenactivated protein kinase (Supplementary Figure S1E) were not involved in the observed IFN-γ reduction exerted by CI. These results suggest that CI interfered with IFN-γ production through reduction of transcription factors relevant for optimal expression of this cytokine.
| CI down-regulates expression of co-stimulatory molecule on dendritic cells in vitro
The obtained results indicate that CI modulated the T cell-mediated immune response during T1D pathogenesis. However, it is reasonable to assume that CI acts first on phagocytic cells due to its particulate nature.
To investigate whether CI exerts direct effect on maturation and DC 
| DISCUSSION
This study shows that the intraperitoneal administration of CI suppresses T1D development in MLDS-treated C57BL/6 mice. The observed effect of CI on T1D was neither strain nor species restricted, judging by its ability to suppress hyperglycemia in both CBA/H mice and DA rats. CI exerted its immunomodulatory activity through modulation of macrophage activity and by boosting the regulatory arm of the immune response.
The propensity of adjuvants to block autoimmunity has been already shown in many cases (Kies & Alvord, 1958; Lee et al., 2008; Sadelain, Qin, Lauzon, et al., 1990; Sadelain, Qin, Sumoski, et al., 1990) . In this study, a single injection of CI (administered alone) provided long-lasting protection from MLDS-triggered T1D in animals. Similar results were obtained with single CFA injection given to NOD mice (Lee et al., 2008 , Tian et al., 2009 .
Compared to these studies that hypothesize the inhibitory effect of the adjuvant on autoreactive cytotoxic T cells, NK, and NKT, we assumed that CI acts first on phagocytic cells. Indeed, our study showed profound effect of CI on macrophage polarization and suppressor function, in terms of lowering the proportion of pro-inflammatory M1 mac r o p h ag e si ns pl e e nan dp a n c r e a t i c infiltrates, and by enhancing their capacity to suppress T cell proliferation in vitro. The influence of the iron on favoring macrophage anti-inflammatory phenotype was shown in the other study performed by Corna et al. (2010) .
Decrease in M1 macrophages after CI treatment probably led to a reduction in the number of activated T cells (CD4 + CD25 low ) observed in the spleen. This effect might be mediated by NO that is produced by the remaining M1 macrophages. NO was already shown to exhibit direct cytostatic effects on T cells and APC or through depletion of L-arginine during the iNOS reaction (Bingisser, Tilbrook, Holt, & Kees, 1998; Bogdan, 2011) . NO can preferentially down-regulate Th1-type cytokines resulting in a Th2 bias (Taylor-Robinson, 1997) . Also, the CI-mediated interference with IL-12 production by phagocytes could also lead to less Th1 reactivity in the presence of NO (Mattner et al., 1993) . Our in vitro experiments confirm that NO might interfere with T cell-mediated responsesincemacrophagesfromCI-treated animals reduced ConA-stimulated T cell proliferation and thus diminished clonal size of autoreactive T cells. In addition to macrophages, dendritic cells might also be the primary target for CI. In vitro experiments confirmed that dendritic cells engulfed CI and consequently reduced the expression of costimulatory molecules CD40 and CD80. Therefore, the potential of dendritic cells to activate autoreactive T cells was significantly down-regulated (at least observed in vitro) or they had become tolerogenic under persistent signaling provided by the presence of CI (Liu & Cao, 2015) . Different T cell subsets have different roles in T1D pathogenesis.
Th1 and Th17 lymphocytes are thought to be generally involved in the promotion of the disease, while Th2 and Treg cells suppress T1D development (Bluestone, Herold, & Eisenbarth, 2010) . Inhibition of Th1 signature cytokine IFN-γ by CI found in regional lymphoid tissues PLN and PP, as well as in the pancreas seems to be a valid explanation for the beneficial effect of the CI in T1D. This is in line with the animal studies that used specific IFN-γ inhibitors for the therapy of autoimmune diabetes induced in DP-BB rat or C57BL/6 mice or NOD mice (Cockfield, Ramassar, Urmson, & Halloran, 1989; Nicoletti et al., 1996 Nicoletti et al., , 1997 . Interesting finding in this study was that mice treated with CI had elevated number of Th17 cells in both PLN and PP.
This could also be a positive outcome of CI treatment since it was shown that in some settings Th17 protected animals against T1D (Candon et al., 2015; Kriegel et al., 2011) . Furthermore, IL-17 silencing did not prevent T1D development in NOD mice (Joseph, Bittner, Kaiser, Wiendl, & Kissler, 2012) again suggesting that Th17 cells might not be involved in T1D pathogenesis or even might exert protective role. In support to this, it was reported that the rise in the level of IL-17 after adjuvant therapy in NOD mice has a protective effect on T1D (Nikoopour et al., 2010) . However, the role for IL-17 in T1D is still controversial as other data suggest that therapeutic effects of adjuvant treatment may be partially due to suppressing Th17 commitment (Gao et al., 2010) , and that blockade of IL-17 may prevent autoimmune diabetogenesis (Kuriya et al., 2013) . The regulatory role of Th17 is especially true within the intestine where these cells participate in the maintenance of intestinal homeostasis rather than inducing inflammation (Zhao et al., 2017) . It has been shown recently that both pathogenic Th17 cells and non-pathogenic regulatory Treg17 cells can be generated from CD4 + T cells under appropriate polarization conditions (Bellemore et al., 2015; Volchenkov, Nygaard, Sener, & Steen Skålhegg, 2017) . These studies support our findings that not all Th17 cells are pathogenic or their up-regulation in the gut immune system is merely a reaction to a change in microbiota composition that occurs during T1D development (Costa et al., 2016) . Deficiency in NKT contributes to the pathogenesis of autoimmune diabetes in NOD mice as they are able to suppress the development of autoreactive T cells (Yang, Bao, & Yoon, 2001) . NKT produce various cytokines, such as IL-4, IFN-γ, IL-17, and IL-10 (Novak & Lehuen, 2011) .
Our study showed that CI treatment elevated number of NKT cells in PLN and PIMC. It is therefore intriguing to speculate that treatment by CI favors protective cytokine secretion profiles (Th2 inclined) in NKT cells. Also, observed elevated IL-17 production could stem from iNKT cells (Cua & Tato, 2010) and therefore could be utilized to suppress the adaptive immunity. This is not in accordance with adjuvant effect of CI observed in EAE model were the CI treatment induced EAE by expanding NK and NKT cell population (Miljkovic et al., 2011) . Different CI effects in vivo could reflect differences between disease models or differences in the CI delivery route.
Inconclusion,wehaveprovidedevidence that CI is effective inhibitor of T1D development. This inhibitory effect might be due, at least in part, to the suppression of innate immune components that could lead to impaired activation and proliferation of T lymphocytes (especially Th1). On the other side, there is a substantial increase in the regulatory arm of the immune system after CI treatment. This notion may have therapeutic implications not only for T1D, but also for other autoimmune diseases with Treg defects, suggesting that CI may serve as a useful therapeutic for reducing inflammation and ameliorating autoimmunity.
